Mizuho reaffirmed their buy rating on shares of Mednax Inc. (NYSE:MD) in a research note published on Tuesday. They currently have a $79.00 price target on the stock.

Analyst Recommendations for Mednax (NYSE:MD)

MD has been the subject of a number of other reports. Jefferies Group reduced their price objective on shares of Mednax from $80.00 to $75.00 and set a buy rating for the company in a research note on Friday, August 26th. Zacks Investment Research lowered shares of Mednax from a buy rating to a hold rating in a research report on Saturday, July 30th. JPMorgan Chase & Co. reduced their price target on shares of Mednax from $85.00 to $80.00 and set an overweight rating for the company in a research report on Friday, July 29th. Finally, Citigroup Inc. reduced their price target on shares of Mednax from $76.00 to $72.00 and set a neutral rating for the company in a research report on Wednesday, August 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and an average price target of $76.11.

Shares of Mednax (NYSE:MD) opened at 64.50 on Tuesday. The stock has a market capitalization of $5.95 billion, a P/E ratio of 18.00 and a beta of 0.56. The firm’s 50-day moving average is $65.57 and its 200 day moving average is $68.19. Mednax has a 1-year low of $61.40 and a 1-year high of $85.10.

Mednax (NYSE:MD) last posted its quarterly earnings data on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.07 by $0.04. Mednax had a net margin of 11.17% and a return on equity of 14.88%. The business had revenue of $772 million for the quarter, compared to the consensus estimate of $775.68 million. During the same quarter last year, the business posted $0.90 EPS. The business’s revenue for the quarter was up 14.1% on a year-over-year basis. On average, analysts expect that Mednax will post $4.14 EPS for the current fiscal year.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the transaction, the director now owns 12,755 shares in the company, valued at $829,202.55. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Nordea Investment Management AB increased its position in shares of Mednax by 317.0% in the second quarter. Nordea Investment Management AB now owns 2,817,940 shares of the company’s stock valued at $204,103,000 after buying an additional 2,142,237 shares during the period. Wedge Capital Management L L P NC bought a new position in shares of Mednax during the second quarter valued at approximately $109,915,000. Vaughan Nelson Investment Management L.P. bought a new position in shares of Mednax during the second quarter valued at approximately $80,335,000. Norges Bank bought a new position in shares of Mednax during the fourth quarter valued at approximately $59,563,000. Finally, Bank of Montreal Can bought a new position in shares of Mednax during the second quarter valued at approximately $34,026,000. Institutional investors own 97.75% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

5 Day Chart for NYSE:MD

Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.